Announcing ClickHouse Cloud: Democratizing lightning-fast insights and analytics
4.10.2022 17:00:00 EEST | Business Wire | Press release
Today, ClickHouse, Inc. announced the launch of ClickHouse Cloud, a lightning-fast cloud-based database that simplifies and accelerates insights and analytics for modern digital enterprises. With no infrastructure to manage, ClickHouse Cloud architecture decouples storage and compute and scales automatically to accommodate modern workloads, so users do not have to size and tune their clusters to achieve blazing-fast query speeds.
Historically, data infrastructure and analytics solutions have been expensive and difficult to manage. Companies frequently bore the expense of specialized experts and infrastructure teams, only to receive unacceptable performance in return, as legacy solutions struggled to scale. The introduction of ClickHouse Cloud, built by the creators of the much-loved open source project, brings enterprise-grade data analytics and lightning-fast insights to the masses. A ClickHouse Cloud user can log in and launch a new service with a few clicks, and start analyzing their own data in under five minutes.
ClickHouse Cloud, initially released in Beta on AWS, and coming soon on other cloud providers, is highly available and secure by default, so users can focus on developing business-critical applications without the overhead of tuning cluster topology settings. Developers can adopt the latest ClickHouse capabilities, and never have to worry about time-consuming manual upgrades. Built on strong security and privacy fundamentals, the service is already SOC 2 Type I and GDPR compliant, with additional certifications in progress.
ClickHouse Cloud is fully self-service, with a simple, transparent pricing model that allows users to pay only for the resources they use without the need to over-provision for peak workloads. Existing ClickHouse users can migrate to ClickHouse Cloud with just a few simple steps, and new users can get started just as easily. ClickHouse Cloud features a robust partner integration ecosystem for data onboarding, data visualization, and language clients, further accelerating developer and analyst productivity.
“ClickHouse was built to enable our users to derive insights in real time from ever-increasing data volumes. Now the experience our open source users have loved for years is available in a simple and easy-to-use cloud service. It takes just a few minutes to get started, and the rich and growing ecosystem of integrations and partners makes it even easier to ingest and analyze data. We believe this intersection of incredibly high speed and amazingly efficient scale delivers critical advantages to our customers,” says Aaron Katz, co-founder and CEO of ClickHouse, Inc.
“With ClickHouse Cloud, our developers can go from concept to delivery on a new analytical feature in days, instead of weeks. And our operations teams do not have to spend cycles tuning cluster performance for even the most demanding workloads,” says Varun Krishnani of Adevinta. “Decoupled storage and compute architecture and usage-based pricing ensures that we don’t have to over-provision infrastructure, and as a result, our business moves even faster to deliver value to our users at a reduced cost.”
"We use ClickHouse Cloud to monitor millions of real-time web performance data points, to ensure we’re getting faster all the time,” says Daunish Aboobaker, VP Engineering at Minted. ”The platform delivers fast and reliable data management, while also proving to be cost efficient and user-friendly."
ClickHouse Cloud is available immediately in Public Beta. Join the hundreds of development teams that have already been using ClickHouse Cloud throughout the company's private preview and early access programs by signing up for a free trial at www.clickhouse.com.
About ClickHouse
ClickHouse is the world's fastest and most resource efficient online analytical column-oriented database management system. Now offered as a secure and scalable serverless offering in the cloud, ClickHouse Cloud allows anyone to effortlessly take advantage of efficient real time analytical processing. Learn more at clickhouse.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221004005244/en/
Contact information
Tanya Bragin
VP, Product
press@clickhouse.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 09:00:00 EEST | Press release
Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Through Reporting (STR) vision and leveraging the combined capabilities of the transaction to deliver more resilient, transparen
AB InBev Reports First Quarter 2026 Results5.5.2026 08:02:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its home market. 27% increase in revenue of no-alcohol beer. 37% increase in revenue of Beyond Beer. 55% increase in Gross Mer
Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 21:25:00 EEST | Press release
Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent
Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 21:00:00 EEST | Press release
CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom